Cysouw Matthijs C F, Kramer Gerbrand M, Frings Virginie, De Langen Adrianus J, Wondergem Mariëlle J, Kenny Laura M, Aboagye Eric O, Kobe Carsten, Wolf Jürgen, Hoekstra Otto S, Boellaard Ronald
Department of Radiology & Nuclear Medicine, VU University Medical Center, Amsterdam, The Netherlands.
Department of Radiology & Nuclear Medicine, VU University Medical Center, Amsterdam, The Netherlands.
Nucl Med Biol. 2017 Aug;51:18-24. doi: 10.1016/j.nucmedbio.2017.05.002. Epub 2017 May 10.
[F]-fluorothymidine ([F]-FLT) is a PET-tracer enabling in-vivo visualization and quantification of tumor cell proliferation. For qualitative and quantitative analysis, adequate knowledge of normal tissue uptake is indispensable. This study aimed to quantitatively investigate baseline tracer uptake of blood pool, lung, liver and bone marrow and their precision, and to assess the longitudinal effect of systemic treatment on biodistribution.
F-FLT-PET(/CT) scans (dynamic or static) of 90 treatment-naïve oncological patients were retrospectively evaluated. Twenty-three patients received double baseline scans, and another 39 patients were also scanned early and late during systemic treatment with a tyrosine kinase inhibitor. Reproducible volume of interest were placed in blood pool, lung, liver, and bone marrow. For semi-quantitative analysis, SUVmean, SUVmax, and SUVpeak with several normalizations were derived.
SUVs of basal lung, liver, and bone marrow were not significantly different between averaged dynamic and static images, in contrast with blood pool and apical lung. Highest repeatability was seen for liver and bone marrow, with repeatability coefficients of 18.6% and 20.4% when using SUVpeak. Systemic treatment with TKIs both increased and decreased normal tissue tracer uptake at early and late time points during treatment.
Simultaneous evaluation of liver and bone marrow uptake in longitudinal response studies may be used to assess image quality, where changes in uptake outside repeatability limits should trigger investigators to perform additional quality control on individual PET images.
For [F]-FLT PET images, liver and bone marrow have low intra-patient variability when quantified with SUVpeak, but may be affected by systemic treatment.
In [F]-FLT-PET response monitoring trials, liver and bone marrow uptake may be used for quality control of [F]-FLT PET images.
[F]-氟胸苷([F]-FLT)是一种正电子发射断层显像(PET)示踪剂,能够在体内可视化并定量分析肿瘤细胞增殖情况。对于定性和定量分析而言,充分了解正常组织摄取情况必不可少。本研究旨在定量研究血池、肺、肝脏和骨髓的基线示踪剂摄取及其精密度,并评估全身治疗对生物分布的纵向影响。
回顾性评估90例未接受过治疗的肿瘤患者的F-FLT-PET(/CT)扫描(动态或静态)。23例患者接受了两次基线扫描,另外39例患者在接受酪氨酸激酶抑制剂全身治疗的早期和晚期也进行了扫描。在血池、肺、肝脏和骨髓中放置可重复的感兴趣区。进行半定量分析时,得出了几种标准化后的平均标准摄取值(SUVmean)、最大标准摄取值(SUVmax)和峰值标准摄取值(SUVpeak)。
与血池和肺尖相比,平均动态图像和静态图像之间,基础肺、肝脏和骨髓的SUV值无显著差异。肝脏和骨髓的重复性最高,使用SUVpeak时,重复性系数分别为18.6%和20.4%。在治疗的早期和晚期,酪氨酸激酶抑制剂全身治疗既增加又降低了正常组织示踪剂摄取。
在纵向反应研究中,同时评估肝脏和骨髓摄取情况可用于评估图像质量,摄取变化超出重复性限度时,研究人员应针对个体PET图像进行额外的质量控制。
对于[F]-FLT PET图像,用SUVpeak定量时,肝脏和骨髓在患者体内的变异性较低,但可能会受到全身治疗的影响。
在[F]-FLT-PET反应监测试验中,肝脏和骨髓摄取可用于[F]-FLT PET图像的质量控制。